Physician profile
Sanford Katims
NPI 1396833430
$1,676.60
in general payments reported to CMS, 2019-2025
12 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $79.56 · 2021: $250 · 2022: $503 · 2023: $181 · 2024: $214 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $465.90 | 2021-2025 | Acuvue |
| Alcon Vision LLC | $367.48 | 2019-2025 | Total30, Precision 1, Precision7 |
| Lumenis Be INC | $148.52 | 2022 | |
| Sun Pharmaceutical Industries INC. | $125.00 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $112.70 | 2024 | Xdemvy |
| Visioneering Technologies, INC. | $92.55 | 2019 | |
| Aerie Pharmaceuticals, INC. | $89.49 | 2021 | |
| Coopervision INC. | $89.25 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $64.08 | 2024-2025 | Infuse |
| Maculogix, INC. | $58.26 | 2019 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Sight Sciences, INC. | $24.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanford Katims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.